# Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer

> **NCT04089189** · PHASE2 · COMPLETED · sponsor: **Impact Therapeutics, Inc.** · enrollment: 93 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** IMP4297

## Key facts

- **NCT ID:** NCT04089189
- **Lead sponsor:** Impact Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-28
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-12-17
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04089189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04089189, "Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04089189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*